Fundraising FoxCowen Healthcare Investments — 2017 Investments
3 investments dated 2017 · listed companies and verified rows first · show all
Kezar Life Sciences is a clinical-stage biotechnology company developing small-molecule therapeutics for immune-mediated diseases and cancer.
BiotechSouth San Francisco, US
John F. Fowler(Executive Officer, Director)inChristopher J. Kirk(Executive Officer, Director)
BoardDr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)
Co-investorsBay City CapitalChiesi VenturesPappas CapitalQiming Venture Partners USASolasta VenturesEcoR1 Capital+1 more
Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy.
BiotechDeep TechHealthtechMedical DevicesLondon, GB
Donald Kohn(Scientific Founder)Adrian Thrasher(Scientific Founder)Frank E. Thomas(Executive Officer)inSteven M. Altschuler(Director)John Curnutte(Director)
BoardBobby Gaspar(Scientific Founder)in
Co-investorsAlbionVCF-Prime CapitalForesite CapitalUCL Technology Fund4BIO CapitalAgent Capital+3 more
Cambridge, MA biotech developing stem cell-derived islet therapy plus an immune-protective device for type 1 diabetes; acquired by Vertex for $950M.
BiotechCambridge, US
Robert Millman(Executive Officer, Director)
BoardTodd Foley(Executive Officer, Director)inMitch Finer(Director)Stephen Knight(Director)inJim Scopa(Director)William Sahlman(Director)
Co-investorsARCH Venture PartnersF-Prime CapitalJDRF T1D FundORI CapitalSlater Technology Fund6 Dimensions Capital+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.